The use of vortioxetine for the correction of depression in Parkinson's disease: an example of clinical cases
https://doi.org/10.14412/2074-2711-2019-3-78-82
Abstract
The prevalence of depression in Parkinson's disease (PD) amounts to as much as 90%. The paper describes patients at different ages and with different durations of PD in its early and advanced stages and with various types of depressive disorder.
The described clinical cases show that depression substantially worsens quality of life in a patient with PD and makes it difficult to choose antiparkinsonian therapy. Depression remains unrecognized on average in half of patients, while only a quarter of patients with identified depression receive timely treatment with antidepressants. PD complicated by depression is characterized by a faster progression and more significantly impaired quality of life and cognitive status than PD without affective disorders. Patients with PD and depressive disorder are characterized by an insufficient response to standard doses of antiparkinsonian drugs, which often leads to an irrational increase in the dose of dopaminergic drugs and to the development of complications.
Difficulties in choosing an antidepressant for PD are associated with the development of a complex multicomponent neurotransmitter imbalance in this disease. The prescription of multimodal antidepressants can solve this problem.
It is necessary to timely detect and correct depression in patients with PD using the currently available drugs and nonpharmacological methods (psychotherapy and physical rehabilitation).
About the Author
I. V. Miliukhina
Institute of Experimental Medicine;
Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
12, Academician Pavlov St., Saint Petersburg 197376;
6/8, Lev Tolstoy St., Saint Petersburg 19708
References
1. Milyukhina IV. Pathogenesis, clinical features, and treatments of depression in Parkinson's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):93–9. (In Russ.). doi: 10.14412/2074-2711-2019-2-93-99
2. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92.
3. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015 Apr;20(2):93-7. doi: 10.1017/S1092852915000139.
4. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424.
5. Koychev I, Okai D. Cognitive-behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review. Evid Based Ment Health. 2017 Feb;20(1):15-20. doi: 10.1136/ eb-2016- 102574. Epub 2017 Jan 10.
6. Tseng MT, Lin CH. Pain in early-stage Parkinson's disease: Implications from clinical features to pathophysiology mechanisms. J Formos Med Assoc. 2017 Aug;116(8):571-581. doi: 10.1016/j.jfma.2017.04.024. Epub 2017 May 19.
7. Zenesini C, Baldin E, Vignatelli L, et al. Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study.; ParkLink Bologna group. J Neurol Sci. 2019 Aug 7;405:116421. doi: 10.1016/j.jns.2019.08.006.
8. Fasano A, Fung VSC, Lopiano L, et al. Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019 Apr 2;19(1): 50. doi: 10.1186/s12883-019-1276-8.
9. Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson's Disease. Semin Neurol. 2017 Apr; 37(2):147-157. doi: 10.1055/s-0037-1602423.
10. Bruggeman C, O'Day CS. Selective Serotonin Reuptake Inhibitor (SSRI) Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019-. 2018 Nov 28
11. Chen G, Hњjer AM, Areberg J, et al. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686. doi: 10.1007/s40262-017-0612-7.
12. Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. J Affect Disord. 2018 Feb;227:787- 794. doi: 10.1016/j.jad.2017.11.081. Epub 2017 Nov 16.
13. Timmer MHM, van Beek MHCT, Bloem BR, et al. What a neurologist should know about depression in Parkinson's disease. Pract Neurol. 2017 Oct;17(5):359-368. doi: 10.1136/practneurol-2017-001650. Epub 2017 Jul 24.
14. Harada T, Ishizaki F, Horie N, et al. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease. Hiroshima J Med Sci. 2011 Dec;60(4):79-82.
15. Zahodne LB, Bernal-Pacheco O, Bowers D, et al. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease? J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):326-30. doi: 10.1176/appi.neuropsych.11090210.
16. Ray Chaudhuri K, Poewe W, Brooks D. Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. Mov Disord. 2018 Jul;33(6): 909-919. doi: 10.1002/mds.27386.
17. Becker C, Brobert GP, Johansson S, et al. Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol. 2011 Mar;18(3):448-53. doi: 10.1111/j.1468-1331.2010.03176.x. Epub 2010 Aug 16.
18. Ng A, Chander RJ, Tan LC, et al.Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. Parkinsonism Relat Disord. 2015 Sep;21(9): 1056-60. doi: 10.1016/j.parkreldis.2015.06.014. Epub 2015 Jun 18.
19. Lee Y, Oh JS, Chung SJ, et al. The presence of depression in de novo Parkinson's disease reflects poor motor compensation. PLoS One. 2018 Sep 19;13(9):e0203303. doi: 10.1371/journal.pone.0203303. eCollection 2018.
20. Zhuo C, Xue R, Luo L, et al. Efficacy of antidepressive medication for depression in Parkinson disease. Medicine (Baltimore). 2017 Jun;96(22):e6698. doi: 10.1097/MD.0000000000006698.
21. Ryan M, Eatmon CV, Slevin JT. Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother. 2019 Aug;20(11): 1351-1363. doi: 10.1080/14656566.2019.1612877. Epub 2019 May 23.
22. Mills KA, Greene MC, Dezube R, et al. Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis. Int J Geriatr Psychiatry. 2018 Apr;33(4):642-651. doi: 10.1002/gps.4834. Epub 2017 Dec 13.
Review
For citations:
Miliukhina IV. The use of vortioxetine for the correction of depression in Parkinson's disease: an example of clinical cases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):78-82. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3-78-82
Views:
1122
Email this article 